In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1

Zitron, Ian M.; Kamson, David Olayinka; Kiousis, Sam; Juhász, Csaba; Mittal, Sandeep

doi:10.4161/cbt.23624

Cited by 33 publications

(29 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In naïve mice with B16-F10 melanoma tumors that received PD-L1 and Cytotoxic T lymphocyte-associated protein 4 (CTLA-4 or CD152) directed ICI therapy, high tracer uptake was observed in the tumor upon irradiation, suggesting that PD-1 PET can be used for ICI treatment monitoring. Natarajan et al injected a 64 Cu-labeled anti-mouse PD-1 Ab in Foxp3 + LuciDTR4 mice, a mouse model that contains high expressing PD-1 Foxp3 + regulatory T cells, bearing (Juhasz et al 2006(Juhasz et al , 2009(Juhasz et al , 2012Zitron et al 2013;Michelhaugh et al 2017;Guastella et al 2016) A2aR…”

Section: Pd-1 Imagingmentioning

confidence: 99%

“…In patients with brain tumors, [ 11 C]AMT-PET demonstrated increased tracer uptake in the tumor compared to normal cortex (Juhasz et al 2006). Moreover, multiple clinical [ 11 C]AMT-PET trials demonstrated prolonged tracer retention and high uptake in NSCLC lesions (Juhasz et al 2009), invasive ductal breast carcinoma lesions Juhasz et al (2012) and meningiomas Zitron et al (2013). Further clinical studies with [ 11 C]AMT-PET demonstrated the ability to differentiate radiation necrosis from recurrent gliomas (Alkonyi et al 2012), and showed a strong association of high tumor [ 11 C] AMT uptake parameters (SUVmax, SUVmean and tumor-to-background ratio) to a significantly decreased 1year survival (Kamson et al 2014).…”

Section: Imaging Other Immune Checkpoint Molecules Ido and Tdo Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Wierstra

Sandker

Aarntzen

et al. 2019

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Immunotherapy with checkpoint inhibitors demonstrates impressive improvements in the treatment of several types of cancer. Unfortunately, not all patients respond to therapy while severe immune-related adverse effects are prevalent. Currently, patient stratification is based on immunotherapy marker expression through immunohistochemical analysis on biopsied material. However, expression can be heterogeneous within and between tumor lesions, amplifying the sampling limitations of biopsies. Analysis of immunotherapy target expression by noninvasive quantitative molecular imaging with PET or SPECT may overcome this issue. In this review, an overview of tracers that have been developed for preclinical and clinical imaging of key immunotherapy targets, such as programmed cell death-1, programmed cell death ligand-1, IDO1 and cytotoxic T lymphocyteassociated antigen-4 is presented. We discuss important aspects to consider when developing such tracers and outline the future perspectives of molecular imaging of immunotherapy markers.

show abstract

Section: Pd-1 Imagingmentioning

confidence: 99%

Section: Imaging Other Immune Checkpoint Molecules Ido and Tdo Imagingmentioning

confidence: 99%

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Wierstra

Sandker

Aarntzen

et al. 2019

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…Following the hypothesis of altered glycolysis in meningiomas, it was shown that different parts of the glycolysis are transformed, including PFK (phosphofructokinase) and LDH (lactate dehydrogenase), which were signi cantly increased in anaplastic meningioma compared to other histological subtypes (12). Additionally, alterations of the tryptophan metabolism were uncovered, which force the immune-escape mechanism to an increased activity of the kynurenine-pathway (13), (14). Today, increased opportunities in bioinformatics and metabolic pro ling allow detecting associations between metabolic networks and clinical parameters to predict metabolic patterns and associated clinical outcome parameters.…”

Section: Introductionmentioning

confidence: 99%

Metabolic Alterations in Meningioma Reflect Clinical Course

Masalha

Daka

Woerner

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundMeningiomas are common brain tumors, defined by an innocent clinical course. However, some meningiomas reveal a malignant transformation and recur within a short time period regardless of their WHO grade. The current study aims to identify potential markers, which can discriminate between benign and malignant meningioma courses. MethodsFor this purpose, we profiled the metabolites of 43 patients with low- and high-grade meningiomas. Tumor specimens were analyzed by NMR analysis; 270 metabolites were identified and clustered with the AutoPipe algorithm. ResultsWe observed two distinct clusters marked by alterations in the glycine-serine, choline or tryptophan metabolism. Both clusters showed significant differences between WHO graduation and proliferation index.ConclusionOur findings suggest that alterations of glycine-serine are associated with a lower proliferation and frequencies of recurrent tumors. Alterations of the choline-tryptophan metabolism causes increased proliferation and recurrence is more common. Our results suggest, that tumor malignancy is reflected by metabolic alterations, which can support histological classifications in order to predict the clinical outcome of patients with meningiomas.

show abstract

“…The LAT facilitates amino acid transport in tumour cells, which in turn use it for protein synthesis. In meningiomas, high LAT1 expression has been described (Zitron et al 2013). Consequently, increased uptake of FDOPA may be observed in these tumours.…”

mentioning

confidence: 98%

“…Consequently, increased uptake of FDOPA may be observed in these tumours. In addition, increased uptake of other amino acid PET tracers in meningiomas has been described, including a series of 10 meningiomas which showed increased uptake of -[ 11 C]methyl-L-tryptophan (AMT) (Zitron et al 2013). as well as of somatostatin radiolabelled analogs (Soto-Montenegro et al 2014).…”

mentioning

confidence: 99%

Incidental meningioma detected with [18F]-FDOPA PET/CT

Stormezand

Glaudemans

Slart

et al. 2018

European J Hybrid Imaging

View full text Add to dashboard Cite

A 59 year old patient was referred to our department to detect disease activity related to clinical symptoms of tiredness, weight loss and an elevated serum serotonine, suspicious of a neuro-endocrine tumour. A 18F-fluoro-l-dihydroxyphenylalanine (FDOPA) PET/CT scan was performed, which showed focally increased uptake in the terminal ileum and in a mesenterial lymph node. Additionally, an area of intense uptake was observed intracranially. Histological analysis confirmed the presence of a WHO grade I meningioma. Few cases of FDOPA PET uptake in meningiomas have been published, underlining it is as a rare finding. Awareness of this potential finding is crucial to avoid misinterpretation as intracerebral metastasis.

show abstract

In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1

Cited by 33 publications

References 46 publications

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Metabolic Alterations in Meningioma Reflect Clinical Course

Incidental meningioma detected with [18F]-FDOPA PET/CT

Contact Info

Product

Resources

About